» Articles » PMID: 37213047

Unique Trans-kingdom Microbiome Structural and Functional Signatures Predict Cognitive Decline in Older Adults

Abstract

The prevalence of age-related cognitive disorders/dementia is increasing, and effective prevention and treatment interventions are lacking due to an incomplete understanding of aging neuropathophysiology. Emerging evidence suggests that abnormalities in gut microbiome are linked with age-related cognitive decline and getting acceptance as one of the pillars of the Geroscience hypothesis. However, the potential clinical importance of gut microbiome abnormalities in predicting the risk of cognitive decline in older adults is unclear. Till now the majority of clinical studies were done using 16S rRNA sequencing which only accounts for analyzing bacterial abundance, while lacking an understanding of other crucial microbial kingdoms, such as viruses, fungi, archaea, and the functional profiling of the microbiome community. Utilizing data and samples of older adults with mild cognitive impairment (MCI; n = 23) and cognitively healthy controls (n = 25). Our whole-genome metagenomic sequencing revealed that the gut of older adults with MCI harbors a less diverse microbiome with a specific increase in total viruses and a decrease in bacterial abundance compared with controls. The virome, bacteriome, and microbial metabolic signatures were significantly distinct in subjects with MCI versus controls. Selected bacteriome signatures show high predictive potential of cognitive dysfunction than virome signatures while combining virome and metabolic signatures with bacteriome boosts the prediction power. Altogether, the results from our pilot study indicate that trans-kingdom microbiome signatures are significantly distinct in MCI gut compared with controls and may have utility for predicting the risk of developing cognitive decline and dementia- debilitating public health problems in older adults.

Citing Articles

Fecal microbiota transplant from long-living Ames dwarf mice alters the microbial composition and biomarkers of liver health in normal mice.

Ashiqueali S, Hayslip N, Chaudhari D, Schneider A, Zhu X, Rubis B Geroscience. 2025; .

PMID: 39904968 DOI: 10.1007/s11357-025-01539-3.


Protection of Alzheimer's disease progression by a human-origin probiotics cocktail.

Prajapati S, Wang S, Mishra S, Jain S, Yadav H Sci Rep. 2025; 15(1):1589.

PMID: 39794404 PMC: 11724051. DOI: 10.1038/s41598-024-84780-8.


Maternal Gut Microbiome-Mediated Epigenetic Modifications in Cognitive Development and Impairments: A New Frontier for Therapeutic Innovation.

Nohesara S, Mostafavi Abdolmaleky H, Dickerson F, Pinto-Tomas A, Jeste D, Thiagalingam S Nutrients. 2025; 16(24.

PMID: 39770976 PMC: 11676351. DOI: 10.3390/nu16244355.


Abnormalities in gut virome signatures linked with cognitive impairment in older adults.

James A, Adil N, Goltz D, Tangudu D, Chaudhari D, Shukla R Gut Microbes. 2024; 16(1):2431648.

PMID: 39676708 PMC: 11651276. DOI: 10.1080/19490976.2024.2431648.


Predicting superagers: a machine learning approach utilizing gut microbiome features.

Kim H, Kim B, Hong S, Song S, Jeong J, Kim G Front Aging Neurosci. 2024; 16:1444998.

PMID: 39314993 PMC: 11417495. DOI: 10.3389/fnagi.2024.1444998.


References
1.
Bajaj J, Hylemon P, Ridlon J, Heuman D, Daita K, White M . Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol. 2012; 303(6):G675-85. PMC: 3468538. DOI: 10.1152/ajpgi.00152.2012. View

2.
Beghini F, McIver L, Blanco-Miguez A, Dubois L, Asnicar F, Maharjan S . Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3. Elife. 2021; 10. PMC: 8096432. DOI: 10.7554/eLife.65088. View

3.
Chen J, Spencer M, Buchongo P, Wang M . Hospital-based Health Information Technology Infrastructure: Evidence of Reduced Medicare Payments and Racial Disparities Among Patients With ADRD. Med Care. 2022; 61(1):27-35. PMC: 9741995. DOI: 10.1097/MLR.0000000000001794. View

4.
Mehta D, Jackson R, Paul G, Shi J, Sabbagh M . Why do trials for Alzheimer's disease drugs keep failing? A discontinued drug perspective for 2010-2015. Expert Opin Investig Drugs. 2017; 26(6):735-739. PMC: 5576861. DOI: 10.1080/13543784.2017.1323868. View

5.
Elhalag K, Nasr-Eldin M, Hussien A, Ahmad A . Potential use of soilborne lytic Podoviridae phage as a biocontrol agent against Ralstonia solanacearum. J Basic Microbiol. 2018; 58(8):658-669. DOI: 10.1002/jobm.201800039. View